Ipilimumab and Nivolumab induced ventricular tachycardia in a patient with metastatic renal cell carcinoma

The immune checkpoint inhibitor (ICIs) as Nivolumab and Ipilimumab is a novel class of medication used in the management of several metastatic malignancies. ICIs can cause immune-related adverse events due to autoreactive T cell activation. Cardiovascular complications comprised myocarditis, conduct...

Descripción completa

Detalles Bibliográficos
Autores principales: Savarapu, Pramod, Abdelazeem, Basel, Isa, Sakiru, Kesari, Kavitha, Kunadi, Arvind
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Taylor & Francis 2021
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8604542/
https://www.ncbi.nlm.nih.gov/pubmed/34804411
http://dx.doi.org/10.1080/20009666.2021.1965708
_version_ 1784601985016659968
author Savarapu, Pramod
Abdelazeem, Basel
Isa, Sakiru
Kesari, Kavitha
Kunadi, Arvind
author_facet Savarapu, Pramod
Abdelazeem, Basel
Isa, Sakiru
Kesari, Kavitha
Kunadi, Arvind
author_sort Savarapu, Pramod
collection PubMed
description The immune checkpoint inhibitor (ICIs) as Nivolumab and Ipilimumab is a novel class of medication used in the management of several metastatic malignancies. ICIs can cause immune-related adverse events due to autoreactive T cell activation. Cardiovascular complications comprised myocarditis, conduction abnormalities, ventricular storm, and cardiomyopathy. Cardiomyopathy is one of the significant side effects highlighted in some of the case reports. The physicians should include autoimmune toxicities as the potential differential diagnosis in patients presenting with an unusual presentation and receiving ICIs. We report a case of a 66-year-old female with advanced renal cell carcinoma who developed cardiomyopathy and ventricular tachycardia from nivolumab and ipilimumab therapy.
format Online
Article
Text
id pubmed-8604542
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Taylor & Francis
record_format MEDLINE/PubMed
spelling pubmed-86045422021-11-20 Ipilimumab and Nivolumab induced ventricular tachycardia in a patient with metastatic renal cell carcinoma Savarapu, Pramod Abdelazeem, Basel Isa, Sakiru Kesari, Kavitha Kunadi, Arvind J Community Hosp Intern Med Perspect Case Report The immune checkpoint inhibitor (ICIs) as Nivolumab and Ipilimumab is a novel class of medication used in the management of several metastatic malignancies. ICIs can cause immune-related adverse events due to autoreactive T cell activation. Cardiovascular complications comprised myocarditis, conduction abnormalities, ventricular storm, and cardiomyopathy. Cardiomyopathy is one of the significant side effects highlighted in some of the case reports. The physicians should include autoimmune toxicities as the potential differential diagnosis in patients presenting with an unusual presentation and receiving ICIs. We report a case of a 66-year-old female with advanced renal cell carcinoma who developed cardiomyopathy and ventricular tachycardia from nivolumab and ipilimumab therapy. Taylor & Francis 2021-11-15 /pmc/articles/PMC8604542/ /pubmed/34804411 http://dx.doi.org/10.1080/20009666.2021.1965708 Text en © 2021 The Author(s). Published by Informa UK Limited, trading as Taylor & Francis Group on behalf of Greater Baltimore Medical Center. https://creativecommons.org/licenses/by-nc/4.0/This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial License (http://creativecommons.org/licenses/by-nc/4.0/ (https://creativecommons.org/licenses/by-nc/4.0/) ), which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Case Report
Savarapu, Pramod
Abdelazeem, Basel
Isa, Sakiru
Kesari, Kavitha
Kunadi, Arvind
Ipilimumab and Nivolumab induced ventricular tachycardia in a patient with metastatic renal cell carcinoma
title Ipilimumab and Nivolumab induced ventricular tachycardia in a patient with metastatic renal cell carcinoma
title_full Ipilimumab and Nivolumab induced ventricular tachycardia in a patient with metastatic renal cell carcinoma
title_fullStr Ipilimumab and Nivolumab induced ventricular tachycardia in a patient with metastatic renal cell carcinoma
title_full_unstemmed Ipilimumab and Nivolumab induced ventricular tachycardia in a patient with metastatic renal cell carcinoma
title_short Ipilimumab and Nivolumab induced ventricular tachycardia in a patient with metastatic renal cell carcinoma
title_sort ipilimumab and nivolumab induced ventricular tachycardia in a patient with metastatic renal cell carcinoma
topic Case Report
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8604542/
https://www.ncbi.nlm.nih.gov/pubmed/34804411
http://dx.doi.org/10.1080/20009666.2021.1965708
work_keys_str_mv AT savarapupramod ipilimumabandnivolumabinducedventriculartachycardiainapatientwithmetastaticrenalcellcarcinoma
AT abdelazeembasel ipilimumabandnivolumabinducedventriculartachycardiainapatientwithmetastaticrenalcellcarcinoma
AT isasakiru ipilimumabandnivolumabinducedventriculartachycardiainapatientwithmetastaticrenalcellcarcinoma
AT kesarikavitha ipilimumabandnivolumabinducedventriculartachycardiainapatientwithmetastaticrenalcellcarcinoma
AT kunadiarvind ipilimumabandnivolumabinducedventriculartachycardiainapatientwithmetastaticrenalcellcarcinoma

Ejemplares similares